LOUISE HECKER to Idiopathic Pulmonary Fibrosis
This is a "connection" page, showing publications LOUISE HECKER has written about Idiopathic Pulmonary Fibrosis.
Connection Strength
2.310
-
Leveraging ageing models of pulmonary fibrosis: the efficacy of nintedanib in ageing. Eur Respir J. 2021 11; 58(5).
Score: 0.624
-
NADPH oxidases: Pathophysiology and therapeutic potential in age-associated pulmonary fibrosis. Redox Biol. 2020 06; 33:101541.
Score: 0.558
-
Reversal of persistent fibrosis in aging by targeting Nox4-Nrf2 redox imbalance. Sci Transl Med. 2014 Apr 09; 6(231):231ra47.
Score: 0.368
-
Nonresolving fibrotic disorders: idiopathic pulmonary fibrosis as a paradigm of impaired tissue regeneration. Am J Med Sci. 2011 Jun; 341(6):431-4.
Score: 0.302
-
Active transcription in the vascular bed characterizes rapid progression in idiopathic pulmonary fibrosis. J Clin Invest. 2023 08 15; 133(16).
Score: 0.176
-
Impaired Myofibroblast Dedifferentiation Contributes to Nonresolving Fibrosis in Aging. Am J Respir Cell Mol Biol. 2020 05; 62(5):633-644.
Score: 0.140
-
New insights into the pathogenesis and treatment of idiopathic pulmonary fibrosis. Drugs. 2011 May 28; 71(8):981-1001.
Score: 0.075
-
NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury. Nat Med. 2009 Sep; 15(9):1077-81.
Score: 0.067